Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo).Shlomit Strulov Shachar, Mira Wollner, Itamar Shafran et al.|Journal of Clinical Oncology|2018Cited by 7